Search results
Results from the WOW.Com Content Network
[13] [16] There are far fewer studies evaluating the side effects of 5α-reductase inhibitors in women. However, due to the known role of DHT in male sexual differentiation, 5α-reductase inhibitors may cause birth defects such as ambiguous genitalia in the male fetuses of pregnant women. As such, they are not used in women during pregnancy. [36]
An endocrinology study by Garcia-Falgueras and Swaab postulated that "In humans, the main mechanism responsible of sexual identity and orientation involves a direct effect of testosterone on the developing brain." [1]: 25 Further, their study puts forward that intrauterine exposure to hormones is largely determinative. Sketching the argument ...
5α-Reductase inhibitors (5-ARIs), also known as dihydrotestosterone (DHT) blockers, are a class of medications with antiandrogenic effects which are used primarily in the treatment of enlarged prostate and scalp hair loss. They are also sometimes used to treat excess hair growth in women and as a component of hormone therapy for transgender ...
Spironolactone stops androgen from binding to receptors, which reduces testosterone and DHT levels and decreases hair loss. Women who are pregnant or trying to get pregnant shouldn’t take ...
Prenatal Testosterone Transfer (also known as prenatal androgen transfer or prenatal hormone transfer) refers to the phenomenon in which testosterone synthesized by a developing male fetus transfers to one or more developing fetuses within the womb and influences development.
DHT binds to receptors in hair follicles, causing the follicle to become smaller (also known as hair miniaturization). Over time, this decrease in diameter causes hair to become thinner and weaker ...
Compared to testosterone, androstanolone (DHT) is less likely to aromatize into estrogen, and therefore it shows less pronounced estrogenic side effects, such as gynecomastia and water retention. On the other hand, androstanolone (DHT) show more significant androgenic side effects, such as acne, hair loss and prostate enlargement.
A separate study, published in the Journal of the American Academy of Dermatology looked at the effects of topical minoxidil in men with pattern hair loss over a total treatment period of 48 weeks.